Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions.
Understanding what surgical advanced practice providers want: A survey of autonomy, tasks, and training preferences across three institutions. Am J Surg. 2026 Sep; 259:116992.
PMID: 42097934
Projected Cancer Screening and Outcomes Under the 2025 Federal Medicaid Eligibility Restrictions.
Projected Cancer Screening and Outcomes Under the 2025 Federal Medicaid Eligibility Restrictions. JAMA Oncol. 2026 Mar 01; 12(3):319-321.
PMID: 41505125
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial.
Adjuvant Chemotherapy Use for Hormone Receptor-Positive, ERBB2-Negative Breast Cancer After RxPONDER Trial. JAMA Netw Open. 2025 12 01; 8(12):e2549109.
PMID: 41632146
Insurance Churn and the COVID-19 Pandemic.
Insurance Churn and the COVID-19 Pandemic. JAMA Health Forum. 2025 06 07; 6(6):e251467.
PMID: 40577007
Young People with Cancer: A Growing Population in Need of United Attention.
Young People with Cancer: A Growing Population in Need of United Attention. Curr Oncol Rep. 2025 Apr; 27(4):333-335.
PMID: 40106216
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US.
Trends and Disparities in the Use of Immunotherapy for Triple-Negative Breast Cancer in the US. JAMA Netw Open. 2025 02 03; 8(2):e2460243.
PMID: 39960669
Patient-reported upper extremity impairment following mastectomy with breast reconstruction: A systematic review.
Patient-reported upper extremity impairment following mastectomy with breast reconstruction: A systematic review. J Plast Reconstr Aesthet Surg. 2025 04; 103:233-247.
PMID: 40009951
Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study.
Social vulnerability is associated with advanced breast cancer presentation and all-cause mortality: a retrospective cohort study. Breast Cancer Res. 2024 Dec 03; 26(1):176.
PMID: 39627859
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer.
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
PMID: 39251516
Validation of the RSClin risk calculator in the National Cancer Data Base.
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 04 15; 130(8):1210-1220.
PMID: 38146744